Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Capital Expenditures (2020 - 2025)

Apellis Pharmaceuticals has reported Capital Expenditures over the past 6 years, most recently at $108000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $108000.0 for Q4 2025, up 440.0% from a year ago — trailing twelve months through Dec 2025 was $313000.0 (down 22.33% YoY), and the annual figure for FY2025 was $313000.0, down 22.33%.
  • Capital Expenditures for Q4 2025 was $108000.0 at Apellis Pharmaceuticals, down from $148000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for APLS hit a ceiling of $851000.0 in Q4 2022 and a floor of $8000.0 in Q1 2025.
  • Median Capital Expenditures over the past 5 years was $148000.0 (2025), compared with a mean of $216631.6.
  • Biggest five-year swings in Capital Expenditures: plummeted 97.33% in 2021 and later skyrocketed 4378.95% in 2022.
  • Apellis Pharmaceuticals' Capital Expenditures stood at $19000.0 in 2021, then skyrocketed by 4378.95% to $851000.0 in 2022, then crashed by 88.84% to $95000.0 in 2023, then tumbled by 78.95% to $20000.0 in 2024, then soared by 440.0% to $108000.0 in 2025.
  • The last three reported values for Capital Expenditures were $108000.0 (Q4 2025), $148000.0 (Q3 2025), and $49000.0 (Q2 2025) per Business Quant data.